These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15270795)

  • 1. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
    Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH; Franken AA; Vincent HH;
    J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
    Sathyapalan T; Atkin SL; Kilpatrick ES
    Diabet Med; 2008 Aug; 25(8):909-15. PubMed ID: 18959603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
    Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
    Constance C; Westphal S; Chung N; Lund M; McCrary Sisk C; Johnson-Levonas AO; Massaad R; Allen C
    Diabetes Obes Metab; 2007 Jul; 9(4):575-84. PubMed ID: 17451425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
    Colhoun HM; Thomason MJ; Mackness MI; Maton SM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2002 Mar; 19(3):201-11. PubMed ID: 11918622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
    Holmberg B; Brännström M; Bucht B; Crougneau V; Dimeny E; Ekspong A; Granroth B; Gröntoft KC; Hadimeri H; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Welin D; Wikdahl AM; Stegmayr BG
    Scand J Urol Nephrol; 2005; 39(6):503-10. PubMed ID: 16303728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.